ScholarIQanswers from OpenAlex & ORCID
Tommaso De Pas
ResearcherPublications, citations & collaboration network
Tommaso De Pas is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Tommaso De Pas have?
ScholarIQindexed works
Tommaso De Pas has 285 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Tommaso De Pas have?
ScholarIQcitation count
Tommaso De Pas has 12,995 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Tommaso De Pas?
ScholarIQh-index
Tommaso De Pas has an h-index of 44 in OpenAlex.
What is the i10-index of Tommaso De Pas?
ScholarIQi10-index
Tommaso De Pas has an i10-index of 125 in OpenAlex.
What is the ORCID of Tommaso De Pas?
ScholarIQorcid
The ORCID for Tommaso De Pas is on the source record.
What is the OpenAlex record for Tommaso De Pas?
ScholarIQopenalex
The OpenAlex for Tommaso De Pas is on the source record.
What are the most-cited papers on Tommaso De Pas?
ScholarIQmost cited works
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne
Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw, Dong-Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin Solomon, Juergen Wolf, Michael Thomas, Martin Schüler, Geoffrey Liu, Armando Santoro, Yvonne Lau, Meredith A. Goldwasser, Anthony Boral, Jeffrey A. Engelman
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Fabio Conforti, Laura Pala, Vincenzo Bagnardi, Tommaso De Pas, Marco Martinetti, Giuseppe Viale, Richard D. Gelber, Aron Goldhirsch
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Johan Vansteenkiste, Byoung Chul Cho, Tõnu Vanakesa, Tommaso De Pas, M. Zieliński, Moon Soo Kim, Jacek Jassem, Masahiro Yoshimura, Jubrail Dahabreh, Haruhiku Nakayama, Libor Havel, Haruhiko Kondo, Tetsuya Mitsudomi, Paul Zarogoulidis, Oleg Gladkov, Katalin Udud, Hirohito Tada, Hans Hoffman, Anders Bugge, Paul Taylor, Emilio Esteban Gonzalez, Mei Lin Liao, Jianxing He, Jean-Louis Pujol, Jamila Louahed, Muriel Debois, Vincent Brichard, C. Debruyne, Patrick Therasse, Nasser K. Altorki
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong‐Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin Solomon, Jürgen Wolf, Michael Thomas, Martin Schüler, Geoffrey Liu, Armando Santoro, Santosh Sutradhar, Siyu Li, Tomasz Szczudlo, A. Yovine, Alice T. Shaw